2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
759
CLINICAL AND SURGICAL APPROACHES TO CHRONIC RHINOSINUSITIS IN
ADULT PATIENTS
¹Asrorov Oybek Akmal oʻg'li
²Bekpo‘latov Muxiddin Hakim oʻg'li
³Bo'riyev Shaxzod Saydullo oʻg'li
¹'²'³Samarkand State Medical University, Department of Otorhinolaryngology No. 2, 2nd year
residents.
https://doi.org/10.5281/zenodo.15512731
Abstract. Chronic rhinosinusitis (CRS) is a multifactorial inflammatory disorder of the
nasal and paranasal sinus mucosa persisting for more than 12 weeks. It significantly impairs
patients’ quality of life through persistent nasal obstruction, facial pain, and olfactory
dysfunction. The complexity of CRS arises from diverse etiologies, heterogeneous
immunopathological mechanisms, and varied clinical presentations, complicating treatment
strategies. This study retrospectively analyzes clinical presentations, diagnostic modalities, and
treatment outcomes of medical and surgical management in adult patients with CRS. Emphasis
is placed on differentiating CRS phenotypes—CRSwNP and CRSsNP—and optimizing
individualized treatment. Functional endoscopic sinus surgery (FESS) remains a cornerstone
for refractory cases, restoring sinus ventilation and drainage. The findings underscore the
importance of integrated care combining medical and surgical approaches for improved
patient outcomes.
Keywords: Chronic rhinosinusitis, nasal polyps, functional endoscopic sinus surgery,
nasal obstruction, sinusitis.
Introduction
Chronic rhinosinusitis (CRS) represents one of the most prevalent chronic inflammatory
diseases worldwide, with significant public health implications. It affects approximately 5–15%
of the adult population globally, with variations influenced by geographic, environmental, and
genetic factors. CRS is characterized clinically by inflammation of the mucosa of the nasal
cavity and paranasal sinuses lasting at least 12 consecutive weeks, despite medical therapy.
Patients often suffer from symptoms such as nasal congestion, nasal discharge, facial pain or
pressure, and impaired olfaction.
CRS is subclassified into two major phenotypes based on endoscopic and
histopathological findings: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps
2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
760
(CRSsNP). These subtypes demonstrate distinct immunopathological pathways, clinical
behaviors, and treatment responses. CRSwNP is typically associated with a type 2 immune
response, eosinophilic inflammation, and a high rate of comorbidities such as asthma and
aspirin-exacerbated respiratory disease (AERD). In contrast, CRSsNP is predominantly
characterized by neutrophilic inflammation and a Th1 immune response, with less frequent
nasal polyp formation.
The burden of CRS extends beyond physical discomfort. It impacts patients’ quality of
life by disrupting sleep, reducing productivity, and contributing to psychological distress,
including depression and anxiety. Moreover, CRS poses a considerable economic burden on
healthcare systems due to frequent physician visits, long-term medication use, and surgical
interventions.
Despite advances in understanding the pathophysiology of CRS, management remains
challenging. Medical therapies, including corticosteroids and antibiotics, aim to reduce mucosal
inflammation and infection, but are often insufficient in refractory cases. Functional endoscopic
sinus surgery (FESS) has revolutionized surgical management by allowing minimally invasive
restoration of sinus ventilation and drainage.
This study aims to evaluate the clinical features, diagnostic tools, and outcomes of both
medical and surgical treatments in adult patients with CRS treated at the Department of
Otorhinolaryngology No. 2, Samarkand State Medical University. Through retrospective
analysis, we seek to contribute to optimizing individualized treatment strategies and improving
patient care.
Pathophysiology
The pathogenesis of CRS is complex and multifactorial, involving intricate interactions
among host immune responses, environmental exposures, microbial agents, and genetic
predispositions. The chronic inflammatory milieu leads to persistent mucosal swelling,
impaired mucociliary clearance, and structural remodeling of the sinonasal mucosa.
Immune Mechanisms
In CRSwNP, the predominant immune profile is characterized by type 2 inflammation
involving eosinophils, mast cells, basophils, and a cytokine milieu rich in interleukins IL-4, IL-
5, and IL-13. These cytokines promote eosinophil recruitment, activation, and survival within
the mucosa, contributing to tissue edema and polyp formation. Eosinophilic inflammation also
induces tissue remodeling through the release of enzymes such as matrix metalloproteinases
(MMPs).
2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
761
Conversely, CRSsNP is typically marked by a Th1-mediated immune response with
neutrophilic predominance and elevated interferon-gamma (IFN-γ) and tumor necrosis factor-
alpha (TNF-α). This leads to fibrosis and mucosal thickening rather than polyp formation.
Microbial Factors
Bacterial colonization and biofilms play crucial roles in perpetuating CRS inflammation.
Biofilms protect bacteria from host immune responses and antibiotic penetration,
leading to persistent infection and chronic inflammation. Common pathogens include
Staphylococcus aureus, Haemophilus influenzae, and Pseudomonas aeruginosa.
Staphylococcus aureus superantigens have been implicated in exacerbating
inflammation, especially in CRSwNP.
Fungal elements have been debated as contributors, but their role remains controversial
and appears less significant than bacterial factors.
Treatment Modalities
Medical Therapy
Medical management is the first-line approach and includes:
Topical Corticosteroids: Nasal sprays or irrigations reduce mucosal inflammation and
polyp size with minimal systemic effects.
Systemic Corticosteroids: Short courses are reserved for severe inflammation or
exacerbations but carry risks of systemic side effects.
Antibiotics: Indicated for bacterial infections or acute exacerbations; however, their role
in chronic management remains limited.
Nasal Saline Irrigation: Helps remove mucus, allergens, and debris, improving
mucociliary clearance.
Adjunctive Therapies: Leukotriene receptor antagonists, antihistamines, and
immunotherapy may be beneficial in select patients with allergic comorbidities.
Surgical Therapy: Functional Endoscopic Sinus Surgery (FESS)
Indicated for patients refractory to medical treatment or with anatomical obstruction.
FESS involves endoscopic removal of polyps and diseased mucosa and widening of
sinus ostia to restore ventilation and drainage while preserving normal tissue.
Postoperative Care
Post-surgical management includes nasal corticosteroids, saline irrigation, and regular
follow-up to monitor healing and prevent recurrence.
Materials and Methods
2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
762
This retrospective study analyzed 150 adult patients diagnosed with CRS at the
Department of Otorhinolaryngology No. 2, Samarkand State Medical University, between
January 2022 and December 2024. Inclusion criteria were adults aged 18 and above with CRS
diagnosed based on EPOS 2020 guidelines, confirmed by nasal endoscopy and CT imaging.
Data collected included demographics, clinical features, endoscopic and radiologic
findings, treatment modalities, and follow-up outcomes over six months.
Patients initially received standardized medical therapy. Those with persistent
symptoms or anatomical obstructions underwent FESS. Outcomes were assessed using
symptom scores, endoscopic findings, and patient satisfaction surveys.
Results
Of the 150 patients, 90 (60%) had CRSsNP and 60 (40%) had CRSwNP. The mean age
was 42.5 years, with a slight male predominance (56%). Nasal congestion was the most
common symptom (92%), followed by facial pain (78%), and olfactory dysfunction (50%).
Medical therapy resulted in symptom improvement in 54 (60%) CRSsNP patients,
evidenced by reduced nasal obstruction and discharge. In contrast, only 18 (30%) CRSwNP
patients responded to medical treatment alone.
FESS was performed on 51 patients: 36 CRSwNP and 15 CRSsNP cases unresponsive
to medical therapy. Postoperative evaluation showed significant symptom relief in 85% of cases,
improved endoscopic appearance, and enhanced quality of life.
No major intraoperative or postoperative complications occurred. Minor adverse events
included transient nasal bleeding and crusting.
Discussion
This study corroborates existing literature emphasizing the heterogeneity of CRS and
the need for tailored treatment. The differential immune profiles between CRSwNP and
CRSsNP explain variations in clinical presentation and treatment response.
The higher success rate of medical therapy in CRSsNP aligns with its neutrophilic, less
aggressive inflammatory nature. Conversely, the eosinophilic inflammation and polyp burden
in CRSwNP often necessitate surgical intervention.
FESS demonstrated excellent outcomes, underscoring its role in refractory CRS
management. Restoration of sinus ventilation facilitates mucosal healing and reduces bacterial
colonization.
2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
763
Postoperative topical corticosteroids are vital in maintaining surgical benefits and
preventing recurrence. Emerging therapies, such as biologics targeting IL-5 and IgE, represent
promising avenues for severe CRSwNP cases.
Conclusion
: Chronic rhinosinusitis remains a challenging condition requiring
comprehensive evaluation and individualized treatment. Medical management effectively
controls inflammation in many CRSsNP cases, while CRSwNP often demands surgical
intervention with FESS. Combined medical and surgical strategies optimize patient outcomes
and quality of life. Continued research into CRS pathophysiology and novel therapeutics will
enhance future care.
References
1.
Taxsinovna N. M. et al. VESTIBULAR VASCULAR REACTIONS IN
ASSESSMENT OF VESTIBULAR DYSFUNCTION IN PATIENTS WITH
CRANIOCEREBRAL TRAUMA //INNOVATIVE ACHIEVEMENTS IN SCIENCE
2024. – 2024. – Т. 3. – №. 29. – С. 104-111.
2.
Uskov A. et al. Modern methods of therapeutic fasting as a way to overcome the
pharmacoresistance of mental pathology //Science and innovation. – 2023. – Т. 2. – №.
D12. – С. 179-185.
3.
Abdukodirova S., . SPECIFIC CHARACTERISTICS AND TREATMENT OF
ACUTE OBSTRUCTIVE BRONCHITIS IN CHILDREN OF EARLY AGE //Science
and innovation. – 2023. – Т. 2. – №. D11. – С. 5-8.
4.
Tahirova J. et al. Insomnia problem causes of sleep disorder, help measures at home
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 521-525.
5.
Sultanov S. et al. Long-term salbi effects of the covid-19 pandemic on the health of
existing residents of alcohol addiction //Science and innovation. – 2023. – Т. 2. – №.
D11. – С. 430-438.
6.
Madaminov M., . Breast cancer detection methods, symptoms, causes, treatment
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 530-535.
7.
Khaitov A. A. et al. Optimization of one-stage sanitation of the nasopharynx and
tympanic
8.
cavity in case of recurrent exudative otitis media // Current scientific research in the
modern
9.
world. - 2018. - No. 1-8. - P. 81-84. (in Russ)
2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
764
10.
Jalalova D. et al. СОЧЕТАННАЯ СТОМАТОЛОГИЧЕСКАЯ И ГЛАЗНАЯ
ПАТОЛОГИЯ //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 91-100.
11.
Tohirova J. D. Jalalova TYPES OF HEMORRHAGIC DISEASES //CHANGES IN
NEWBOENS, THEIR EARLY DIAGNOSIS.-2022.
12.
Tahirova J. et al. Neurose causes and mechanisms of development, symptoms, treatment,
prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 515-520.
13.
Kiyomov I., . IMPROVING SURGICAL TREATMENT METHODS FOR PATIENTS
WITH NASAL PATHOLOGY //Science and innovation. – 2023. – Т. 2. – №. D11. –
С. 226-231.
14.
Sarkisova
V.
et
al.
CYTOKINE
PROFILE
IN
PATIENTS
WITH
GRANULOMATOSIS WITH POLYANGIITIS (WEGENER'S) //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 336-343.
15.
Sarkisova V., Lapasova Z., O. Rakhmanov INFLAMMATORY DISEASES OF THE
PELVIC WOMEN ORGANS. – 2023.
16.
Jalalova D., Raxmonov X., . РОЛЬ С–РЕАКТИВНОГО БЕЛКА В ПАТОГЕНЕЗЕ
СОСУДИСТЫХ
ЗАБОЛЕВАНИЙ
ОРГАНА
ЗРЕНИЯ
У
БОЛЬНЫХ
АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ //Science and innovation. – 2022. – Т. 1. – №.
D8. – С. 114-121.
17.
Malakhov A. et al. Modern views on the treatment and rehabilitation of patients with
dementia //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 322-329.
18.
Jalalova D., Raxmonov X., . ЗНАЧЕНИЕ ДИСФУНКЦИИ ЭНДОТЕЛИЯ В
РАЗВИТИЕ РЕТИНОПАТИИ У БОЛЬНЫХ АГ И ПУТИ ЕГО КОРРЕКЦИИ
//Science and innovation. – 2022. – Т. 1. – №. D8. – С. 101-113.
19.
Madaminov M., .Acute tonsillitis (angina) causes, complications, diagnosis, treatment,
prevention //Science and innovation. – 2022. – Т. 1. – №. D8. – С. 771-779.
20.
F. The problem of insomnia causes of sleep disorder, remedies at home //Science and
innovation. – 2023. – Т. 2. – №. D1. – С. 79-84.
21.
Sattarova S., FEATURES OF ELECTROPHYSIOLOGICAL METHODS FOR
GUILLAIN–BARRÉ SYNDROME //Science and innovation. – 2023. – Т. 2. – №. D10.
– С. 199-204.
22.
F. Hymoritis symptoms, treatment, methods of folk medicine, prevention //Science and
innovation. – 2023. – Т. 2. – №. D1. – С. 72-78.
2025
MAY
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 5
765
23.
Zhalalova D. et al. INFORMATION POINT OF PERIPHERAL BLOOD INDEXES IN
THE DIAGNOSIS OF THE ETIOLOGY OF OPTIC NERVE DAMAGE //Science and
innovation. – 2023. – Т. 2. – №. D11. – С. 124-130.
24.
Takhsinovna N. M., Musinovna R. K. CHARACTERISTICS OF COMPLAINTS
FROM
WORKERS
IN
NOISE
PROFESSIONS,
HAVING
HEARING
IMPAIRMENTS //Health Horizon: Congress on Public Health and Biomedical
Sciences. – 2025. – Т. 1. – №. 1. – С. 28-30.
25.
Rotanov, A., . (2023). Elderly epilepsy: neurophysiological aspects of non-psychotic
mental disorders. Science and innovation, 2(D12), 192-197.
26.
Taxsinovna N. M. et al. VESTIBULAR VASCULAR REACTIONS IN
ASSESSMENT OF VESTIBULAR DYSFUNCTION IN PATIENTS WITH
CRANIOCEREBRAL TRAUMA //INNOVATIVE ACHIEVEMENTS IN SCIENCE
2024. – 2024. – Т. 3. – №. 29. – С. 104-111.
